stoxline Quote Chart Rank Option Currency Glossary
Candel Therapeutics, Inc. (CADL)
5.17  -0.29 (-5.31%)    04-19 16:00
Open: 5.44
High: 5.55
Volume: 515,312
Pre. Close: 5.46
Low: 5.05
Market Cap: 152(M)
Technical analysis
2024-04-19 5:08:20 PM
Short term     
Mid term     
Targets 6-month :  8.82 1-year :  13.31
Resists First :  7.55 Second :  11.39
Pivot price 5.09
Supports First :  1.34 Second :  1.11
MAs MA(5) :  5.55 MA(20) :  4.2
MA(100) :  1.92 MA(250) :  1.49
MACD MACD :  1 Signal :  1
%K %D K(14,3) :  38.8 D(3) :  41
RSI RSI(14): 58.7
52-week High :  11.39 Low :  0.66
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CADL ] has closed below upper band by 49.0%. Bollinger Bands are 437.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.56 - 5.59 5.59 - 5.61
Low: 4.98 - 5.01 5.01 - 5.04
Close: 5.12 - 5.17 5.17 - 5.22
Company Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Headline News

Fri, 19 Apr 2024
How Is The Market Feeling About Candel Therapeutics? - Candel Therapeutics (NASDAQ:CADL) - Benzinga

Mon, 15 Apr 2024
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Growth in Short Interest - MarketBeat

Mon, 15 Apr 2024
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer (CADL) - Seeking Alpha

Fri, 12 Apr 2024
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag - Zacks Investment Research

Sat, 06 Apr 2024
Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded - Yahoo Finance

Sat, 06 Apr 2024
Candel Therapeutics, Inc.'s (NASDAQ:CADL) market cap up US$148m last week, benefiting both individual investors ... - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 29 (M)
Shares Float 18 (M)
Held by Insiders 34.7 (%)
Held by Institutions 16.4 (%)
Shares Short 161 (K)
Shares Short P.Month 196 (K)
Stock Financials
EPS -1.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.43
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -40.4 %
Return on Equity (ttm) -125.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.28
Qtrly Earnings Growth 0 %
Operating Cash Flow -34 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -3.95
PEG Ratio 0
Price to Book value 11.75
Price to Sales 0
Price to Cash Flow -4.44
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android